Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation

Pediatric Transplantation

Volumn 9, Issue 6, 2005, Pages 746-753

  Butani, Lavjay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol; Kidney; Pediatric; Pravastatin

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIPID; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; TACROLIMUS; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MALE; MORBIDITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEINS; MALE; MONITORING, PHYSIOLOGIC; PRAVASTATIN; TIME FACTORS; TRIGLYCERIDES;

EID: 27944451945     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00373.x     Document Type: Article

References (49)

1. PAREKH RS, CARROLL CE, WOLFE RA, PORT FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002: 141: 191-197.
2. TEJANI A, SULLIVAN EK, ALEXANDER S, FINE R, HARMON W, LILIENFELD D. Posttransplant deaths and factors that influence the mortality rate in North American children. Transplantation 1994: 57: 547-553.
3. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996: 28: 53-61.
4. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996: 49: 1379-1385.
5. AMANN K, RITZ E, WIEST G, KLAUS G, MALL G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994: 4: 1814-1819.
6. CHAUVEAU P, CHADEFAUX B, COUDE M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993: 41: S72-S77.
7. CRESSMAN MD, ABOOD D, O'NEIL J, HOFF HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids 1994: 67-68: 419-427.
8. JOVEN J, VILELLA E, AHMAD S, CHEUNG MC, BRUNZELL JD. Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 1993: 43: 410-418.
9. SHARMA AK, MYERS TA, HUNNINGHAKE DB, MATAS AJ, KASHTAN CE. Hyperlipidemia in long-term survivors of pediatric renal transplantation. Clin Transplant 1994: 8: 252-257.
10. ONG CS, POLLOCK CA, CATERSON RJ, MAHONY JF, WAUGH DA, IBELS LS. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine (Baltimore) 1994: 73: 215-223.
11. MASSY ZA, GUIJARRO C, WIEDERKEHR MR, MA JZ, KASISKE BL. Chronic renal allograft rejection: immunologic and non-immunologic risk factors. Kidney Int 1996: 49: 518-524.
12. DELUCCHI A, MARIN V, TRABUCCO G, et al. Dyslipidemia and dietary modification in Chilean renal pediatric transplantation. Transplant Proc 2001: 33: 2008-2013.
13. HOLDAAS H, HARTMANN A, STENSTROM J, DAHL KJ, BORGE M, PFISTER P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995: 76: 102A-106A.
14. YOSHIMURA N, OHMORI Y, TSUJI T, OKA T. Effect of pravastatin on renal transplant recipients treated with cyclosporine 4-year follow-up. Transplant Proc 1994: 26: 2632-2633.
15. HOLDAAS H, JARDINE AG, WHEELER DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001: 60: 1990-1997.
16. GOLDBERG RB, ROTH D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995: 76: 107A-109A.
17. HOLDAAS H, FELLSTROM B, JARDINE AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003: 361: 2024-2031.
18. PALINSKI W, TSIMIKAS S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002: 13: 1673-1681.
19. KOBASHIGAWA JA, KATZNELSON S, LAKS H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995: 333: 621-627.
20. KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996: 61: 1469-1474.
21. KASISKE BL, HEIM-DUTHOY KL, SINGER GG, WATSCHINGER B, GERMAIN MJ, BASTANI B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001: 72: 223-227.
22. BUTANI L, PAI MV, MARKER SP. Pilot study describing the use of pravastatin in peiatric enal transplant recipients. Pediatr Transplant 2003: 7: 179-184.
23. SCHWARTZ GJ, BRION LP, SPITZER A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Cli North Am 1987: 34: 571-590.
24. US DEPARTMENT OF HEALTH AND HUMAN SERVICES. Lipids Research Clinics Program. The Lipid Research Clinics Population Studies Data Book, Volume 1. The Prevalence Study. Bethesda, MD: NIH, 1980, No 80-1527.
25. BALLANTYNE CM, HOOGEVEEN RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J 2003: 146: 227-233.
26. KNIPSCHEER HC, BOELEN CC, KASTELEIN JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996: 39: 867-871.
27. PENSON MG, FRICKER FJ, THOMPSON JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001: 20: 611-618.
28. KRMAR RT, FERRARIS JR, RAMIREZ JA, SORROCHE P, LEGAL S, CAYSSIALS A. Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol 2002: 17: 540-543.
29. ARGENT E, KAINER G, AITKEN M, ROSENBERG AR, MACKIE FE. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 2003: 7: 38-42.
30. BRINDLEY DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int J Obes Relat Metab Disord 1995: 19 (Suppl. 1): S69-S75.
31. HIRSCH LJ, MAZZONE T. Dexamethasone modulates lipoprotein metabolism in cultured human monocyte-derived macrophages. Stimulation of scavenger receptor activity. J Clin Invest 1986: 77: 485-490.
32. CHAN MK, VARGHESE Z, MOORHEAD JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981: 19: 625-637.
33. BAGDADE J, CASARETTO A, ALBERS J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 1976: 87: 38-48.
34. Fox CS, LONGENECKER JC, POWE NR, et al. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol 2004: 61: 299-307.
35. RUDAS L, PFLUGFELDER PW, MCKENZIE FN, MENKIS AH, NOVICK RJ, KOSTUK WJ. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990: 66: 1135-1138.
36. SALAZAR A, MANA J, PINTO X, ARGIMON JM, HURTADO I, PUJOL R. Corticosteroid therapy increases HDL-cholesterol concentrations, in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta 2002: 320: 59-64.
37. LEMIEUX I, HOUDE I, PASCOT A, et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 2002: 62: 1839-1847.
38. MOULIN P, APPEL GB, GINSBERG HN, TALL AR. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 1992: 33: 1817-1822.
39. IGEL-KORCAGOVA A, RAAB P, BRENSING KA, et al. Cholesterol metabolism in patients with chronic renal failure on hemodialysis. J Nephrol 2003: 16: 850-854.
40. SHOJI T, NISHIZAWA Y, NISHITANI H, YAMAKAWA M, MORII H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992: 41: 1653-1661.
41. SAVDIE E, GIBSON JC, STEWART JH, SIMONS LA. High-density lipoprotein in chronic renal failure and after renal transplantation. Br Med J 1979: 1: 928-930.
42. Guarnieri GF, MORACCHIELLO M, CAMPANACCI L, et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978: 8: S26-30.
43. VAZIRI ND, LIANG K, PARKS JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001: 59: 2192-2196.
44. KINOSIAN B, GLICK H, GARLAND G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994: 121: 641-647.
45. MANNINEN V, TENKANEN L, KOSKINEN P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992: 85: 37-45.
46. STRONG JP, MALCOM GT, McMAHAN CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999: 281: 727-735.
47. KUME N, KITA T, MIKAMI A, et al. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine. Circulation 1989: 79: 1084-1090.
48. MIYAZAKI A, KOIEYAMA T, SHIMADA Y, et al. Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits. J Atheroscler Thromb 2004: 11: 22-28.
49. SARWAL MM, VIDHUN JR, ALEXANDER SR, SATTERWHITE T, MILLAN M, SALVATIERRA O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331-1339.